, Volume 177, Issue 1–2, pp 185–194

Functional MRI study of working memory in MDMA users

  • F. Gerard Moeller
  • Joel L. Steinberg
  • Donald M. Dougherty
  • Ponnada A. Narayana
  • Larry A. Kramer
  • Perry F. Renshaw
Original Investigation



Methylene-dioxymethamphetamine (MDMA) is known to cause degeneration of serotonin nerve terminals after acute doses in animals. Similarly, behavioral studies in human MDMA users regularly find abnormalities in memory, mood, and impulse control. However, studies of brain function using brain imaging in MDMA users have been less consistent.


The purpose of this study was to determine, using functional magnetic resonance imaging (fMRI), whether individuals with a self-reported history of MDMA use would differ from non-MDMA using controls on activation while performing a working memory task.


Fifteen MDMA using subjects and 19 non-MDMA using controls underwent fMRI scanning while performing the immediate and delayed memory task (IMT/DMT). The study was based on a block design in which the delayed memory task (DMT) alternated with the immediate memory task (IMT), which served as a control condition. FMRI scans were acquired on a 1.5 T scanner, using a gradient echo echoplanar pulse sequence.


Random effects SPM99 analysis showed significantly greater activation (whole volume corrected cluster P<0.05) during the DMT relative to the IMT in the MDMA subjects compared with the control subjects in the medial superior frontal gyrus, in the thalamus extending into putamen, and in the hippocampus.


Although these effects could be due to other drugs used by MDMA users, these results are consistent with behavioral problems that are associated with MDMA use, and with animal studies on the effects of MDMA on brain function.


MDMA Functional magnetic resonance imaging Working memory Substance abuse 


  1. Adler RJ (1981) The geometry of random fields. Wiley, New YorkGoogle Scholar
  2. Bolla KI, McCann UD, Ricaurte GA (1998) Memory impairment in abstinent MDMA (“ecstasy”) users. Neurology 51:1532–1537PubMedGoogle Scholar
  3. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW (2000) Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med 343:450–456CrossRefPubMedGoogle Scholar
  4. Brett M, Anton J-L, Valabregue R, Poline J-B (2002) Region of interest analysis using an SPM toolbox [abstract]. Presented at the Eighth International Conference on Functional Mapping of the Human Brain, June 2–6, 2002, Sendai, Japan. NeuroImage 16Google Scholar
  5. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M (2003) Long-term effects of “ecstasy” use on serotonin transporters of the brain investigated by PET. J Nucl Med 44:375–384PubMedGoogle Scholar
  6. Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE (2000) Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res 98:15–28Google Scholar
  7. Cohen RS (1995) Subjective reports on the effects of the MDMA (“ecstasy”) experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 19:1137–1145CrossRefPubMedGoogle Scholar
  8. Colado MI, Granados R, O’Shea E, Esteban B, Green AR (1999) The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, “eve”) on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA (“ecstasy”). Pharmacol Toxicol 84:261–266PubMedGoogle Scholar
  9. Colado MI, O’Shea E, Esteban B, Green AR (2001) Studies on the neuroprotective effect of the enantiomers of AR-A008055, a compound structurally related to clomethiazole, on MDMA (“ecstasy”)-induced neurodegeneration in rat brain. Psychopharmacology 157:82–88CrossRefPubMedGoogle Scholar
  10. Cox RW (1996) AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 29:162–173PubMedGoogle Scholar
  11. Croft RJ, Mackay AJ, Mills AT, Gruzelier JG (2001) The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology 53:373–379CrossRefGoogle Scholar
  12. Dafters RI, Hoshi R, Talbot AC (2003) Contribution of cannabis and MDMA (“ecstasy”) to cognitive changes in long-term polydrug users. Psychopharmacology Aug 30 [EPub ahead of print]Google Scholar
  13. Daumann J, Fimm B, Willmes K, Thron A, Gouzoulis-Mayfrank E (2003a) Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study. Cognit Brain Res 16:479–487CrossRefGoogle Scholar
  14. Daumann J, Schnitker R, Weidemann J, Schnell K, Thron A, Gouzoulis-Mayfrank E (2003b) Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users. Neuroreport 14:1983–1987CrossRefPubMedGoogle Scholar
  15. Desmond JE, Chen SH, DeRosa E, Pryor MR, Pfefferbaum A, Sullivan EV (2003) Increased frontocerebellar activation in alcoholics during verbal working memory: an fMRI study. Neuroimage 19:1510–1520CrossRefPubMedGoogle Scholar
  16. Donaldson W (1992) Measuring recognition memory. J Exp Psychol [Gen Sect] 121:275–277Google Scholar
  17. Dougherty DM (1999) IMT/DMT immediate memory tasks & delayed memory task: a research tool for studying attention and memory processes. Neurobehavioral Research Laboratory and Clinic, University of Texas Houston Health Science Center, HoustonGoogle Scholar
  18. D’Esposito M, Aguirre GK, Zarahn E, Ballard D, Shin RK, Lease J (1998) Functional MRI studies of spatial and nonspatial working memory. Brain Res Cognit Brain Res 7:1–13PubMedGoogle Scholar
  19. Ernst T, Chang L, Jovicich J, Ames N, Arnold S (2002) Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology 59:1343–1349PubMedGoogle Scholar
  20. First MB, Spitzer RL, Gibbon M, Williams JB (1996) Structured clinical interview for DSM-IV axis I disorders patient edition. Biometrics Research Department, New York State Psychiatric Institute, New YorkGoogle Scholar
  21. Friston KJ, Holmes, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ (1995a) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2:189–210Google Scholar
  22. Friston KJ, Holmes AP, Poline JB, Price CJ, Frith CD (1995b) Detecting activations in PET and fMRI: levels of inference and power. Neuroimage 40:223–235Google Scholar
  23. Gamma A, Buck A, Berthold T, Vollenweider FX (2001) No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [H2(15)O]-positron emission tomography study. J Clin Psychopharmacol 21:66–71CrossRefPubMedGoogle Scholar
  24. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 68:719–725PubMedGoogle Scholar
  25. Hatzidimitriou G, McCann UD, Ricaurte GA (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (±)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19:5096–5107PubMedGoogle Scholar
  26. Holmes A, Friston KJ (1998) Generalisability, random effects & population inference. Neuroimage 7:S754Google Scholar
  27. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH (2003) Preliminary evidence of hippocampal dysfunction in adolescent MDMA (“ecstasy”) users: possible relationship to neurotoxic effects. Psychopharmacology Nov 28 [Epub ahead of print]Google Scholar
  28. Lee JH, Telang FW, Springer CS Jr, Volkow ND (2003) Abnormal brain activation to visual stimulation in cocaine abusers. Life Sci 73:1953–1961CrossRefPubMedGoogle Scholar
  29. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA (“ecstasy”) on brain serotonin neurons in human beings. Lancet 352:1433–1437PubMedGoogle Scholar
  30. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA (1999) Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study. Psychopharmacology 143:417–425PubMedGoogle Scholar
  31. McGregor IS, Clemens KJ, Van der Plasse G, Li KM, Hunt GE, Chen F, Lawrence AJ (2003) Increased anxiety 3 months after brief exposure to MDMA (“ecstasy”) in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 28:1472–1484CrossRefPubMedGoogle Scholar
  32. Moeller FG, Dougherty DM, Steinberg JL, Swann AC, Silverman PB, Ruiz P, Barratt ES (2002) Heavy “ecstasy” use is associated with increased impulsivity. Addict Disord Treat 1:47–52CrossRefGoogle Scholar
  33. Morgan MJ (1998) Recreational use of “ecstasy” (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 19:252–264CrossRefPubMedGoogle Scholar
  34. Morgan MJ, McFie L, Fleetwood H, Robinson JA (2002) Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 159:294–303PubMedGoogle Scholar
  35. Obrocki J, Buchert R, Vaterlein O, Thomasius R, Beyer W, Schiemann T (1999) Ecstasy—long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 175:186–188PubMedGoogle Scholar
  36. Ogawa S, Lee TM, Kay AR, Tank DW (1990) Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 87:9868–9872PubMedGoogle Scholar
  37. Pan HS, Wang RY (1991) The action of (±)-MDMA on medial prefrontal cortical neurons is mediated through the serotonergic system. Brain Res 543:56–60CrossRefPubMedGoogle Scholar
  38. Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 139:261–268CrossRefPubMedGoogle Scholar
  39. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K (1998) Cognitive performance in recreational users of MDMA of “ecstasy”: evidence for memory deficits. J Psychopharmacol 12:79–83PubMedGoogle Scholar
  40. Parrott AC, Sisk E, Turner JJ (2000) Psychobiological problems in heavy “ecstasy” (MDMA) polydrug users. Drug Alcohol Depend 60:105–110PubMedGoogle Scholar
  41. Petersson KM, Nichols TE, Poline JB, Holmes AP (1999) Statistical limitations in functional neuroimaging. II. Signal detection and statistical inference. Philos Trans R Soc Lond B Biol Sci 354:1261–1281CrossRefPubMedGoogle Scholar
  42. Pfefferbaum A, Desmond JE, Galloway C, Menon V, Glover GH, Sullivan EV (2001) Reorganization of frontal systems used by alcoholics for spatial working memory: an fMRI study. Neuroimage 14:7–20CrossRefPubMedGoogle Scholar
  43. Poline JB, Holmes A, Worsley K, Friston KJ (1997) Making statistical inferences. In: Frackowiac RSJ, Friston KJ, Frith CD, Dolan RJ, Mazziotta JC (eds) Human brain function. Academic, San Diego, pp 85–106Google Scholar
  44. Quate L, McBean DE, Ritchie IM, Olverman HJ, Kelly PA (2004) Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilization in the dark agouti rat. Psychopharmacology Feb 20 [Epub ahead of print]Google Scholar
  45. Reneman L, Endert E, de Bruin K, Lavalaye J, Feenstra MG, de Wolff FA, Booij J (2002) The acute and chronic effects of MDMA (“ecstasy”) on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 26:387–396CrossRefPubMedGoogle Scholar
  46. Ricaurte GA, McCann UD, Szabo Z, Scheffel U (2000a) Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Toxicol Lett 112–113:143–146Google Scholar
  47. Ricaurte GA, Yuan J, McCann UD (2000b) (±)3,4-Methylenedioxymethamphetamine (“ecstasy”)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42:5–10PubMedGoogle Scholar
  48. Rodgers J (2000) Cognitive performance amongst recreational users of “ecstasy”. Psychopharmacology 151:19–24PubMedGoogle Scholar
  49. Schifano F (2000) Potential human neurotoxicity of MDMA (“ecstasy”): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. Neuropsychobiology 42:25–33PubMedGoogle Scholar
  50. Schmidt CJ, Taylor VL (1987) Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 36:4095–4102CrossRefPubMedGoogle Scholar
  51. Semple DM, Ebmeier KP, Glabus MF, O’Carroll RE, Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (“ecstasy”) users. Br J Psychiatry 175:63–69PubMedGoogle Scholar
  52. Simon NG, Mattick RP (2002) The impact of regular ecstasy use on memory function. Addiction 97:1523–1529CrossRefPubMedGoogle Scholar
  53. Talairach J, Tournoux P (1988) Co-planar stereotaxic atlas of the human brain, 1st edn. Thieme, New YorkGoogle Scholar
  54. Tapert SF, Cheung EH, Brown GG, Frank LR, Paulus MP, Schweinsburg AD, Meloy MJ, Brown SA (2003) Neural response to alcohol stimuli in adolescents with alcohol use disorder. Arch Gen Psychiatry 60:727–735CrossRefPubMedGoogle Scholar
  55. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 167:85–96PubMedGoogle Scholar
  56. Volkow ND, Mullani N, Gould KL, Adler S, Krajewski K (1988) Cerebral blood flow in chronic cocaine users: a study with positron emission tomography. Br J Psychiatry 152:641–648PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • F. Gerard Moeller
    • 1
  • Joel L. Steinberg
    • 1
  • Donald M. Dougherty
    • 1
  • Ponnada A. Narayana
    • 2
  • Larry A. Kramer
    • 2
  • Perry F. Renshaw
    • 3
  1. 1.Department of Psychiatry and Behavioral SciencesUniversity of Texas Health Science Center HoustonHoustonUSA
  2. 2.Department of RadiologyUniversity of Texas Health Science Center HoustonHoustonUSA
  3. 3.McLean Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations